申请人:Beijing Reciprocapharmaceuticals Co., Ltd.
公开号:EP3882241A1
公开(公告)日:2021-09-22
Disclosed herein is a compound of Formula (I) with a Btk inhibitory activity, wherein all the variables are as defined herein. The compound can be used for the treatment of diseases such as autoimmune diseases, xenogeneic immune diseases, cancers or thromboembolic diseases. Also disclosed is a pharmaceutical composition comprising a compound of Formula (I). Futher provided is a compound capable of inhibiting the activity of Bruton's tyrosine kinase by covalent binding.
本文公开了一种具有 Btk 抑制活性的式 (I) 化合物,其中所有变量如本文所定义。该化合物可用于治疗自身免疫性疾病、异种免疫性疾病、癌症或血栓栓塞性疾病等疾病。还公开了一种包含式(I)化合物的药物组合物。还提供了一种能够通过共价结合抑制布鲁顿酪氨酸激酶活性的化合物。